Taking weight loss injections for a month: what actually happens

The situation: you have one pen, one month, and a question about whether that is enough

Picture this. A plain, unbranded box arrives via DPD. Inside is your first Mounjaro or Wegovy pen, together with a Patient Information Leaflet that is longer than you expected. You inject on day one. Life carries on. A few weeks later you are wondering whether this one month is a trial run, a complete course, or just the start of something longer.

It is the start. Neither Mounjaro nor Wegovy is designed as a short course. The weight loss injection pathway follows a titration schedule (each dose step lasting around four weeks) precisely because the therapeutic doses (10 mg or 15 mg for Mounjaro; 1.7 mg or 2.4 mg for Wegovy, or up to 7.2 mg with the newly approved higher-dose pen) take time to reach, and because starting low reduces the nausea and other gastrointestinal effects that tend to peak after a dose change then settle. One month at the starter dose tells you a lot about tolerability. It tells you almost nothing yet about results.

That is not a criticism of the medicines, it is simply how they work. The appetite-suppressing and metabolic effects accumulate. Patients in the SURMOUNT-1 trial, which ran for 72 weeks, saw the greatest weight reductions in the second half of the study, as detailed in the SURMOUNT-1 paper published in the New England Journal of Medicine. A month is the entrance, not the destination.

How long these medicines are actually licensed to be used

There is no upper time limit written into the UK product licences for Mounjaro or Wegovy. The NHS England guidance on weight management injections frames these as long-term treatments for a long-term condition. NICE's appraisal of tirzepatide notes that treatment should be reviewed if less than five percent of body weight is lost after six months at the highest tolerated dose, which implies the expectation that treatment runs at least that long.

Wegovy (semaglutide) under NICE guidance is recommended for a maximum of two years within specialist NHS services, though that restriction applies specifically to NHS commissioning under TA875 rather than to private prescribing. On the private route, how long you continue is a clinical decision made between you and your prescriber, based on your progress, tolerability and goals.

If you are thinking about what a longer supply looks like before committing, our page on a three-month supply explains how that works practically. And if your question is more fundamental (whether these injections are right for you at all) our clinical team covers the basics on the eligibility overview page.

What stopping after one month actually means

You are not obligated to continue. These are not subscriptions; at nume, every repeat order is clinically re-reviewed and nothing ships automatically. If after a month you decide not to continue, that is entirely your decision.

What tends to happen physiologically, though, is worth understanding. The weight that people lose while on GLP-1 medicines is largely regained over time after stopping, the NHS patient guidance on tirzepatide notes this plainly. The medicines work partly by reducing appetite through gut-hormone signalling; when the medicine leaves your system, appetite returns. Stopping at the end of month one, when you are still on the starter dose and have not yet reached the dose where appetite suppression is most pronounced, means you are unlikely to have experienced the full effect in either direction.

None of that is to push anyone into a longer course, only to give an honest picture of what the clinical evidence shows. Some people do use a single month as a reset, or find after clinical review that the medicine is not right for them. The key is making that call with your prescriber rather than simply not reordering.

It is also worth knowing that the cost of a single month of treatment is not cheaper per dose than a longer commitment, there is no bulk discount at a legitimate UK pharmacy. If pricing is part of the calculation, our cost context page covers what the market actually looks like and why the lowest listing is not always the right one for a prescription medicine.

Safety considerations that do not disappear after one month

Whether you take these medicines for a month or a year, the same safety framework applies. You must have a valid prescription following a full clinical assessment. The most common effects are gastrointestinal (nausea, loose stools, constipation, indigestion) and they are most likely to appear in the first weeks or after a dose increase, which means month one can feel rougher than later months once tolerance builds.

Serious effects are uncommon but real. The MHRA has highlighted acute pancreatitis as a known, infrequent risk: severe stomach pain that radiates to the back, persisting rather than coming in waves, warrants urgent medical attention. You can report any suspected side effects using the MHRA Yellow Card scheme. Beyond the GI profile, there are circumstances where these medicines are not suitable, pregnancy, breastfeeding, or planning to conceive; a history of certain thyroid or pancreatic conditions; being under 18. These are assessed during the consultation, not assumed.

If you are wondering how the process of getting a prescription actually works, or whether you would qualify, the page on accessing weight loss injections walks through the realistic steps. When you are ready, our prescribers review consultations the same day, a real clinician, not automated software. Speak to our prescribers to start that conversation.